Physician profile
Jeremy A Mazurek
NPI 1336440254
$142,177.22
in general payments reported to CMS, 2019-2025
23 companies · $79K in 2025
The $79K reported for 2025 was more than what 96% of Advanced Heart Failure and Transplant Cardiology providers received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,960 · 2020: $3,029 · 2021: $4,122 · 2022: $7,356 · 2023: $29K · 2024: $11K · 2025: $79K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $51K · Consulting Fee: $48K · Travel and Lodging: $11K · Food and Beverage: $9,037 · Education: $163.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $51,311.25 |
| Consulting Fee | $48,437.50 |
| Travel and Lodging | $10,760.52 |
| Food and Beverage | $9,037.44 |
| Education | $162.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $62,322.31 | 2019-2025 | Uptravi, Opsumit |
| Merck Sharp & Dohme LLC | $34,331.81 | 2023-2025 | Winrevair, Verquvo, Capvaxive |
| United Therapeutics Corporation | $33,078.95 | 2019-2025 | Remodulin, Tyvaso, Orenitram |
| Abbott Laboratories | $4,994.18 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems, Perclose Prostyle |
| Janssen Scientific Affairs, LLC | $4,500.00 | 2023-2024 | |
| Cvrx, INC. | $1,002.64 | 2024-2025 | Barostim Neo System |
| Medtronic Vascular, INC. | $387.95 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $317.74 | 2024-2025 | Farxiga, Wainua |
| Abiomed | $311.08 | 2022-2024 | Impella |
| Alnylam Pharmaceuticals INC. | $200.17 | 2025 | Amvuttra |
| Bayer Healthcare Pharmaceuticals INC. | $169.26 | 2019-2025 | |
| Gilead Sciences, INC. | $160.35 | 2019 | |
| Medtronic, INC. | $87.14 | 2021-2024 | Micra, Cobalt Dr Mri Surescan, Linq II |
| Edwards Lifesciences Corporation | $83.51 | 2024-2025 | Sapien 3 Ultra Resilia |
| Esperion Therapeutics, INC. | $49.13 | 2025 | Nexletol |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $43.71 | 2025 | Rybelsus, Ozempic |
| Bridgebio Pharma, INC. | $38.33 | 2025 | Attruby |
| Impulse Dynamics (USA) INC. | $31.82 | 2024 | Optimizer |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $21.14 | 2023 | Lifevest |
| Novartis Pharmaceuticals Corporation | $19.65 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.55 | 2025 | Jardiance |
| Sensible Medical Innovations INC | $9.80 | 2025 | Reds System |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeremy Mazurek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.